Sucraid® is the first and only pharmaceutical drug therapy approved by the FDA as a simple, safe, and effective enzyme replacement therapy of the genetically determined sucrase deficiency that is part of congenital sucrase-isomaltase deficiency (CSID).
Read more about CSID
Sucraid® is a pale yellow, clear solution with a pleasant, sweet taste. It is a simple and effective enzyme replacement therapy. Sucraid® is easy to use—simply take with meals and snacks.
Please visit our newest websites:
Our CSID patient website for patients and caregivers living with CSID
Find out about our Genetic Prevalence Screening study
CSID will be featured on The Balancing Act, Lifetime Television's morning show, as part of the "Behind the Mystery: Rare & Genetic Diseases" series. Watch Dr. William Treem (a pediatric gastroenterologist), two CSID patients, and their families discuss CSID symptoms, diagnosis, and treatment options.
July 26th, August 2nd, and August 30th on Lifetime Television at:
7-8 AM EDT
7-8 AM PDT
6-7 AM CDT
For a complete discussion of indications, usage, contraindications, warnings, precautions, adverse reactions, and overdosage, please see full prescribing information attached. Do not use Sucraid® with patients known to be hypersensitive to yeast, yeast products, or glycerin (glycerol). Sucraid may contain papain which can cause allergic reactions in some patients. Adverse experiences with Sucraid in clinical trials were generally minor and were frequently associated with underlying disease. In clinical studies of up to 54 months duration, physicians treated a total of 52 patients with Sucraid. The adverse experiences and respective number of patients reporting each event were as follows: abdominal pain(4), vomiting(3), nausea(2), diarrhea(2), constipation(2), insomnia(1), headache(1), nervousness(1), and dehydration(1). Note: diarrhea and abdominal pain can be a part of the clinical presentation of the genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency. The effects of Sucraid have not been evaluated in patients with secondary (acquired) disaccharidase deficiency. In one clinical trial, one patient, a four year old boy who was being treated for asthma, experienced severe wheezing necessitating admission into the ICU. While reported reactions are extremely rare, care should be taken when administering initial doses of Sucraid to observe any signs of acute hypersensitivity reaction. Care should be taken to administer initial doses of Sucraid near a facility where acute hypersensitivity reactions can be adequately treated.1